Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs KMTS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KMTS Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

KMTS Overall Winner 6-Pillar Tally: FEMY 2 – 2 KMTS (2 Tie) Matrix Metrics: FEMY 2 – 6 KMTS

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas KMTS carries 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs KMTS
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
KMTS NASDAQ Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$27.97
-2.34% 1D
Market Cap $1.7B
TTM Revenue $107M
Forward P/E N/M
Beta / 30D Vol 1.84β · 63% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 21.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $29.27 · SMA50: $27.43

6-Pillar Scorecard Institutional Category Breakdown (FEMY 2 – 2 KMTS)

Columns: Metric · FEMY · KMTS
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x 15.5x
2. Growth & Scale KMTS
Revenue Growth (YoY) -18.9% +59.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $107M
Market Cap $11.9M $1.7B
3. Profitability & Quality KMTS
Gross Margin 60.9% 53.9%
Operating Margin -763.9% -134.5%
Net Profit Margin 0.0% -140.4%
Return on Equity (ROE) -425.0% -73.7%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$19M -$117M
Cash Flow Margin N/A -109.7%
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (2) vs KMTS (6)
Institutional Metric FEMY KMTS Criterion Row Edge
Market Capitalization
Scale
$11.9M $1.7B Larger Scale KMTS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-18.9% +59.9% Higher Growth KMTS
Operating Margin (TTM)
Profitability
-763.9% -134.5% Higher Margin KMTS
Net Profit Margin
Profitability
0.0% -140.4% Higher Margin FEMY
Return on Equity (ROE)
Capital Efficiency
-425.0% -73.7% Higher ROE KMTS
52-Week Range Position
Momentum
17% ($0–$6) 73% ($17–$32) Stronger Trend KMTS
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 1.84β · 63% Vol Lower Realized Risk KMTS
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% 53.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · 15.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) -$117M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KMTS +25.1 pp
FEMY: -22.42% · KMTS: +2.68%
3M Horizon KMTS +41.96 pp
FEMY: -41.82% · KMTS: +0.14%
6M Horizon FEMY +210.03 pp
FEMY: +252.81% · KMTS: +42.78%
1Y Horizon FEMY +42.5 pp
FEMY: +54.78% · KMTS: +12.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FEMY Revenue KMTS Revenue FEMY Op. Margin KMTS Op. Margin Margin Leader
FY2020 $0M N/A -668.0% N/A FEMY
FY2021 $0M N/A -706.7% N/A FEMY
FY2022 $0M N/A -961.7% N/A FEMY
FY2023 $0M N/A -1353.4% N/A FEMY
FY2024 $0M $30M -1091.8% -305.8% KMTS
FY2025 $0M $60M -767.0% -177.8% KMTS
FY2026 N/A $100M N/A -141.6% KMTS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KMTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KMTS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and -134.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs KMTS Key Questions & Quantitative Answers

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas KMTS carries 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KMTS leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with KMTS at +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), FEMY cumulative revenue shifted N/A while KMTS shifted +233.3%. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KMTS.

FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus KMTS (-73.7% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.